MA42613A - Filtration en profondeur chargée de protéines de liaison à un antigène - Google Patents

Filtration en profondeur chargée de protéines de liaison à un antigène

Info

Publication number
MA42613A
MA42613A MA042613A MA42613A MA42613A MA 42613 A MA42613 A MA 42613A MA 042613 A MA042613 A MA 042613A MA 42613 A MA42613 A MA 42613A MA 42613 A MA42613 A MA 42613A
Authority
MA
Morocco
Prior art keywords
antigen binding
binding protein
deep filtration
loaded
filtration loaded
Prior art date
Application number
MA042613A
Other languages
English (en)
Inventor
Rafael Gonzalez
Hai Hoang
Junfen Ma
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56802689&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42613(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA42613A publication Critical patent/MA42613A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44791—Microapparatus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA042613A 2015-08-13 2016-08-12 Filtration en profondeur chargée de protéines de liaison à un antigène MA42613A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562204831P 2015-08-13 2015-08-13

Publications (1)

Publication Number Publication Date
MA42613A true MA42613A (fr) 2018-06-20

Family

ID=56802689

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042613A MA42613A (fr) 2015-08-13 2016-08-12 Filtration en profondeur chargée de protéines de liaison à un antigène

Country Status (15)

Country Link
US (2) US11098079B2 (fr)
EP (2) EP3334747B1 (fr)
JP (1) JP6889149B2 (fr)
DK (1) DK3334747T3 (fr)
ES (1) ES2964640T3 (fr)
FI (1) FI3334747T3 (fr)
HR (1) HRP20231544T1 (fr)
HU (1) HUE064252T2 (fr)
LT (1) LT3334747T (fr)
MA (1) MA42613A (fr)
PL (1) PL3334747T3 (fr)
PT (1) PT3334747T (fr)
SG (1) SG10202101105XA (fr)
SI (1) SI3334747T1 (fr)
WO (1) WO2017027861A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
CN107973487B (zh) * 2017-11-14 2021-03-02 东华大学 一种染整废水层级处理工艺及装置
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
AR121061A1 (es) * 2020-01-15 2022-04-13 Hoffmann La Roche Métodos para disminuir impurezas de los procesos de fabricación de proteínas recombinantes
CN111410688A (zh) * 2020-03-13 2020-07-14 苏州智享众创孵化管理有限公司 一种提高双特异性抗体纯度的分离纯化方法
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5237054A (en) 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
WO1996004925A1 (fr) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugues et anticorps de type humain specifiques contre des lymphomes malins a cellules b et des cellules leucemiques
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
AUPQ599700A0 (en) 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
ES2387546T3 (es) 2001-05-11 2012-09-25 Amgen Inc. Péptidos y moléculas relacionadas que se unen a TALL-1
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
EP2087908B1 (fr) 2001-06-26 2018-05-30 Amgen Inc. Anticorps opgl
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
CA2456648C (fr) 2001-08-23 2011-08-16 Genmab A/S Anticorps humains specifiques diriges contre l'interleukine 15 (il-15)
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2497884C (fr) 2002-09-06 2013-10-22 Brian Varnum Anticorps monoclonal therapeutique anti-il-1r1 humain
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
DK3284753T3 (da) 2002-10-17 2021-07-05 Genmab As Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
DE60335915D1 (de) 2002-12-20 2011-03-10 Amgen Inc Myostatin hemmende bindungsstoffe
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
WO2005019266A2 (fr) 2003-07-15 2005-03-03 Amgen Inc. Anticorps neutralisants anti-ngf humains utilises comme inhibiteurs selectifs de la voie de ngf
PT1682180E (pt) 2003-11-04 2010-02-10 Novartis Vaccines & Diagnostic Anticorpos monoclonais antagonistas anti-cd40 e métodos para a sua utilização
US7638606B2 (en) 2003-11-07 2009-12-29 Immunex Corporation Antibodies that bind interleukin-4 receptor
EP1712240B1 (fr) 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Preparation medicamenteuse aqueuse stable contenant un anticorps
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
WO2007035283A1 (fr) 2005-09-15 2007-03-29 Wyeth Floculation de proteines au moyen de sels
US20080132688A1 (en) * 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
WO2008051448A2 (fr) * 2006-10-19 2008-05-02 Tolerx, Inc. Procédés et compositions pour l'élimination efficace de la protéine a de préparations de molécules de liaison
LT3597659T (lt) 2007-07-09 2023-05-10 Genentech, Inc. Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
DE102008037678A1 (de) * 2008-08-14 2010-02-25 Sartorius Stedim Biotech Gmbh Tiefenfilterschicht mit anorganischem Schichtdoppelhydroxid
EP2921501A1 (fr) 2008-10-20 2015-09-23 Abbvie Inc. Isolement et purification d'anticorps par chromatographie d'affinité de la protéine A
EP2424889B1 (fr) * 2009-04-30 2015-08-12 Ablynx N.V. Procédé de production d'anticorps à domaines
MX2012004711A (es) 2009-10-20 2012-05-23 Abbott Lab Aislamiento y purificacion de los anticuerpos anti-il-13 al usar cromatografia de afinidad con proteina a.
US20120208986A1 (en) 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
WO2011140405A1 (fr) * 2010-05-07 2011-11-10 Millipore Corporation Milieu de clarification amélioré
CA2799502A1 (fr) 2010-05-18 2011-11-24 Abbvie Inc. Appareil et procede de purification de proteines
RU2610667C2 (ru) 2010-10-11 2017-02-14 Эббви Бахамаз Лтд., Способ очистки белков
AU2011317021B2 (en) * 2010-10-20 2015-07-09 Medimmune, Llc Methods for processing inclusion bodies
WO2012125735A1 (fr) 2011-03-15 2012-09-20 Abott Laboratories Approche intégrée à isolement et purification d'anticorps
JP6027104B2 (ja) 2011-07-08 2016-11-16 イー・エム・デイー・ミリポア・コーポレイシヨン 使い捨てバイオテクノロジー方法のための改良されたデプスフィルター
FR2977893B1 (fr) 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
HUE035941T2 (en) 2011-08-02 2018-05-28 Baxalta GmbH Systems and Methods for Recombinant Production Methods to Increase Protein Yield
WO2013028330A2 (fr) * 2011-08-19 2013-02-28 Emd Millipore Corporation Procédés pour réduire le niveau d'une ou de plusieurs impuretés dans un échantillon pendant un procédé de purification de protéines
SG11201403437TA (en) 2011-12-22 2014-07-30 Genentech Inc Ion exchange membrane chromatography
US20140010820A1 (en) * 2012-05-21 2014-01-09 Abbvie, Inc. Novel purification of non-human antibodies using protein a affinity chromatography
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2682168A1 (fr) * 2012-07-02 2014-01-08 Millipore Corporation Dispositif de tirage et métier à filer
WO2014100443A2 (fr) * 2012-12-20 2014-06-26 Medimmune, Llc Procédés de production d'immunoconjugués
US10174076B2 (en) 2013-06-04 2019-01-08 Agency For Science, Technology And Research Protein purification process
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
GB201318840D0 (en) 2013-10-24 2013-12-11 Univ Leeds Method and device for protein preparation
EP3066123A1 (fr) 2013-11-07 2016-09-14 AbbVie Inc. Isolement et purification d'anticorps
CN106164086A (zh) 2014-02-27 2016-11-23 新加坡科技研究局 抗体纯化方法
US20170191101A1 (en) 2014-03-17 2017-07-06 Regeneron Pharmaceuticals, Inc. Clarification of mammalian cell culture
EP3145951A1 (fr) 2014-06-24 2017-03-29 InSight Biopharmaceuticals Ltd. Procédés de purification d'anticorps
EP3236772A4 (fr) 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Procédés permettant de purifier des protéines recombinantes

Also Published As

Publication number Publication date
JP6889149B2 (ja) 2021-06-18
PL3334747T3 (pl) 2024-04-02
EP4209499A1 (fr) 2023-07-12
SI3334747T1 (sl) 2024-02-29
EP3334747A1 (fr) 2018-06-20
EP3334747B1 (fr) 2023-09-27
JP2018526357A (ja) 2018-09-13
SG10202101105XA (en) 2021-03-30
ES2964640T3 (es) 2024-04-08
LT3334747T (lt) 2023-12-27
PT3334747T (pt) 2023-12-12
US20210363180A1 (en) 2021-11-25
FI3334747T3 (fi) 2023-11-30
HRP20231544T1 (hr) 2024-03-15
DK3334747T3 (da) 2023-12-11
US20180230180A1 (en) 2018-08-16
US11098079B2 (en) 2021-08-24
HUE064252T2 (hu) 2024-02-28
WO2017027861A1 (fr) 2017-02-16

Similar Documents

Publication Publication Date Title
DK3625259T3 (da) Anti-sirpalpha-antistoffer
DK3548652T3 (da) Fremgangsmåder til proteinanalyse
DK3344654T3 (da) Anti-lag-3-antistoffer
ZA201804317B (en) Altered april binding antibodies
DK3356413T3 (da) Anti-tigit-antigenbindingsproteiner og fremgangsmåder til anvendelse deraf
DK3332006T3 (da) Hidtil ukendte anti-PD-L1-antistoffer
DK3292141T3 (da) Fusionsproteiner
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3221347T3 (da) Muterede immunoglobulin-bindende polypeptider
HK1250737A1 (zh) 結合cd79的抗體分子
MA42613A (fr) Filtration en profondeur chargée de protéines de liaison à un antigène
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
ZA201701912B (en) Antigen binding proteins that bind cxcr5
DK3606961T3 (da) Garp-tgf-beta-antistoffer
DK3325514T3 (da) Her2-bindende proteiner baseret på di-ubiquitin-muteiner
DK3362477T3 (da) Antigenbindingsproteiner, der aktiverer leptinreceptoren
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3253785T3 (da) Hidtil ukendte egfr-bindingsproteiner
DK3265123T3 (da) Antistoffer, anvendelser og fremgangsmåder
DK3099791T3 (da) Protein
IL259181A (en) Opposite ph-salt gradients for improved protein separations
DK3262168T3 (da) Værtscelleproteinmodifikation
MA45695A (fr) Protéines de liaison à un antigène qui se lient à cxcr3
DK3132031T3 (da) Carbohydratbindende protein
DK3484921T3 (da) Anti-IL-22R antistoffer